WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 29, 2016

proyectovikingo@proyectovikingo.es

Contents

| • | • , | C | CD 1 | |
|----|------|----|-------------|-----|
| П. | 1St. | Ωt | Tah | IPS |

| 1 | Participant characteristics | : |
|---------------------------------------|-------------------------------|--------------|
| 2 | According to Local Recurrence | |
| 3 | According to Metastasis | |
| 4 | According to Exitus | |
| 5 | Incidence by outcome [95% CI] | |
| | | |
| List | of Figures | |
| \mathbf{List} | | ŗ |
| \mathbf{List} | Local Recurrence | |
| 1 | Local Recurrence | 7 |
| $\begin{array}{c} 1 \\ 2 \end{array}$ | Local Recurrence | 9 |
| 1 2 3 | Local Recurrence | 7 9 10 |

Table 1: Participant characteristics

| All N=198 | [A] | r T 1 | |
|---|--------------------------------|------------------|-----|
| Age 66.7 (10.9) 198 Sex: Men 157 (79.3%) 198 Tumor level: 198 0-6cm 78 (39.4%) 7-12cm 101 (51.0%) 13-15cm 19 (9.60%) Tumor stage: 198 0 19 (9.60%) 19 II 63 (31.8%) 11 III 54 (27.3%) 11 Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Hartmann 13 (66.2%) 198 Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | · · | • | N |
| Sex: Men 157 (79.3%) 198 Tumor level: 198 0-6cm 78 (39.4%) 7-12cm 7-12cm 101 (51.0%) 19 13-15cm 19 (9.60%) 19 Tumor stage: 198 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Hartmann 13 (66.2%) 198 Hartmann 13 (65.7%) 198 Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 No-satisfactory 3 (1.52%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 | | | |
| Tumor level: 198 0-6cm 78 (39.4%) 7-12cm 101 (51.0%) 13-15cm 19 (9.60%) Tumor stage: 198 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Hartmann 13 (66.2%) 198 Hartmann 13 (65.7%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Age | , , | 198 |
| 0-6cm 78 (39.4%) 7-12cm 101 (51.0%) 13-15cm 19 (9.60%) Tumor stage: 198 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Anterior resection 131 (66.2%) 198 Hartmann 13 (6.57%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Months to Metastasis 30 (15.2%) 198 Exitus 37 (18.7%) 198 | · · · | 157 (79.3%) | 198 |
| 7-12cm 101 (51.0%) 13-15cm 19 (9.60%) Tumor stage: 198 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) IIII 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection Anterior resection 131 (66.2%) Hartmann 13 (6.57%) Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) Partial 51 (25.8%) No-satisfactory 3 (1.52%) Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Tumor level: | | 198 |
| 13-15cm 19 (9.60%) Tumor stage: 198 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) IIII 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Hartmann 13 (66.2%) 198 Hartmann 13 (6.57%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 No-satisfactory 3 (1.52%) 198 Nonths to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | 0-6cm | 78 (39.4%) | |
| Tumor stage: 19 (9.60%) 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) IIII 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Anterior resection 131 (66.2%) 198 Hartmann 13 (6.57%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | 7-12cm | 101 (51.0%) | |
| 0 19 (9.60%) I 63 (31.8%) III 54 (27.3%) III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Anterior resection 131 (66.2%) 198 Hartmann 13 (6.57%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | $13\text{-}15\mathrm{cm}$ | 19 (9.60%) | |
| I 63 (31.8%) III 54 (27.3%) IIII 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 198 Anterior resection 131 (66.2%) 198 Hartmann 13 (6.57%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Tumor stage: | | 198 |
| III 54 (27.3%) III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) Anterior resection 131 (66.2%) Hartmann 13 (6.57%) Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | 0 | 19 (9.60%) | |
| III 62 (31.3%) Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) Anterior resection 131 (66.2%) Hartmann 13 (6.57%) Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | I | 63 (31.8%) | |
| Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 18 Anterior resection 131 (66.2%) 18 Hartmann 13 (6.57%) 198 Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | II | $54\ (27.3\%)$ | |
| Neoadjuvant treatment 124 (62.6%) 198 Type of resection: 198 Abdominoperineal resection 54 (27.3%) 18 Anterior resection 131 (66.2%) 18 Hartmann 13 (6.57%) 198 Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | III | 62(31.3%) | |
| Type of resection: 198 Abdominoperineal resection 54 (27.3%) Anterior resection 131 (66.2%) Hartmann 13 (6.57%) Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 198 Partial 51 (25.8%) 198 No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Neoadjuvant treatment | | 198 |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | , | 198 |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Abdominoperineal resection | on 54 (27.3%) | |
| Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 144 (72.7%) Partial 51 (25.8%) 51 (25.8%) No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Anterior resection | 131~(66.2%) | |
| Perforation 5 (2.53%) 198 Invasion circumferential margin 18 (9.14%) 197 Mesorrecto quality: 198 Satisfactory 144 (72.7%) 144 (72.7%) Partial 51 (25.8%) 51 (25.8%) No-satisfactory 3 (1.52%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Hartmann | 13~(6.57%) | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Perforation | , | 198 |
| Mesorrecto quality: 198 Satisfactory 144 (72.7%) Partial 51 (25.8%) No-satisfactory 3 (1.52%) Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Invasion circumferential margi | n 18 (9.14%) | 197 |
| Partial 51 (25.8%) No-satisfactory 3 (1.52%) Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | _ | , | 198 |
| Partial 51 (25.8%) No-satisfactory 3 (1.52%) Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Satisfactory | 144 (72.7%) | |
| No-satisfactory 3 (1.52%) Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Partial | ` / | |
| Recidive 7 (3.54%) 198 Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | No-satisfactory | (/ | |
| Months to recidive 47.0 [25.0;60.0] 198 Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | · · | , | 198 |
| Metastasis 30 (15.2%) 198 Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Months to recidive | , | 198 |
| Months to Metastasis 45.0 [19.0;60.0] 198 Exitus 37 (18.7%) 198 | Metastasis | 2 | 198 |
| Exitus 37 (18.7%) 198 | Months to Metastasis | (/ | 198 |
| , | | . , , | 198 |
| Months to exitus 48.5 25.0;60.0 198 | Months to exitus | 48.5 [25.0;60.0] | 198 |

Table 2: According to Local Recurrence

| | | | Crude | | Multivariate | |
|---------------------------------|--------------------|---------------|-----------------------|---------|--------------------------|---------|
| | No event n= 191 | Event n= 7 | HR | p-value | HR | p-value |
| Age (10y) | 6.68 (1.08) | 6.30 (1.33) | 0.75 [0.39;1.43] | 0.378 | 1.03 [0.46; 2.32] | 0.944 |
| Sex: Men | 151 (79.1%) | 6 (85.7%) | 1.61 [0.19;13.3] | 0.661 | 5.21 [0.31; 87.24] | 0.251 |
| Tumor level: | (, , , , | (| [,] | | , , | |
| 0-6cm | 74 (38.7%) | 4 (57.1%) | 114873772 [0.00;.] | 0.998 | 95806662.52 [0.00; Inf] | 0.999 |
| 7-12cm | 98 (51.3%) | 3(42.9%) | 62054667 [0.00;.] | 0.999 | 76627894.59 [0.00; Inf] | 0.999 |
| Tumor stage: | , | , | | | | |
| 0 | 19 (9.95%) | 0 (0.00%) | 0.00 [0.00;.] | 0.999 | 0.00 [0.00; Inf] | 0.999 |
| II | 52 (27.2%) | 2(28.6%) | 1.14 [0.16;8.08] | 0.898 | 1.62 [0.16; 16.30] | 0.681 |
| III | 59 (30.9%) | 3(42.9%) | 1.78 [0.30;10.6] | 0.529 | $0.70 [\ 0.05;\ 9.57]$ | 0.792 |
| Neoadjuvant treatment | 118 (61.8%) | 6~(85.7%) | 4.06 [0.49;33.8] | 0.194 | 16.66 [0.51; 541.24] | 0.113 |
| Type of resection: | | | | | | |
| Abdominoperineal resection | $51\ (26.7\%)$ | 3(42.9%) | 2.52 [0.51;12.5] | 0.259 | 0.89 [0.04; 17.72] | 0.937 |
| Hartmann | 12~(6.28%) | $1\ (14.3\%)$ | 3.90[0.40;37.9] | 0.241 | 4.85 [0.35; 68.20] | 0.241 |
| Perforation | 3~(1.57%) | 2(28.6%) | 15.2[2.93;78.6] | 0.001 | 362.53 [10.47;12551.69] | 0.001 |
| Invasion circumferential margin | 16 (8.42%) | 2(28.6%) | 4.16 [0.80;21.6] | 0.090 | 12.99 [0.81; 207.93] | 0.07 |
| Mesorrecto quality: | | | | | | |
| Partial | 50~(26.2%) | 1~(14.3%) | $0.44 \ [0.05; 3.68]$ | 0.450 | 0.06 [0.00; 2.33] | 0.13 |
| No-satisfactory | 3(1.57%) | 0 (0.00%) | 0.00 [0.00;.] | 0.998 | 0.00 [0.00; Inf] | 0.999 |

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence




Table 3: According to Metastasis

| | | | Crude | | Multivaria | te | |
|---------------------------------|--------------------|--------------|-------------------|---------|-------------------------|---------|-----|
| | No event n= 168 | Event $n=30$ | HR | p-value | HR | p-value | N |
| Age (10y) | 6.66 (1.07) | 6.71 (1.18) | 1.05 [0.75;1.46] | 0.793 | 1.15 [0.81; 1.63] | 0.45 | 198 |
| Sex: Men | 134 (79.8%) | 23 (76.7%) | 0.84 [0.36;1.96] | 0.689 | $1.39 \ [0.53; \ 3.61]$ | 0.501 | 198 |
| Tumor level: | , | , | . , , | | , , | | 198 |
| 0-6cm | 65 (38.7%) | 13 (43.3%) | 1.82 [0.41;8.05] | 0.432 | 2.35 [0.36;15.43] | 0.375 | |
| 7-12cm | 86 (51.2%) | 15 (50.0%) | 1.53 [0.35;6.69] | 0.572 | 1.55 [0.33; 7.38] | 0.582 | |
| Tumor stage: | , | , , | | | | | 198 |
| 0 | 19 (11.3%) | 0 (0.00%) | 0.00 [0.00;.] | 0.997 | 0.00 [0.00; Inf] | 0.997 | |
| II | 49 (29.2%) | 5 (16.7%) | 0.95 [0.29; 3.12] | 0.934 | 1.02 [0.29; 3.61] | 0.981 | |
| III | 43~(25.6%) | 19 (63.3%) | 3.93 [1.57; 9.85] | 0.004 | 3.70 [1.35;10.13] | 0.011 | |
| Neoadjuvant treatment | 104 (61.9%) | 20 (66.7%) | 1.32 [0.62;2.82] | 0.476 | 1.47 [0.60; 3.64] | 0.403 | 198 |
| Type of resection: | , , | , , | | | | | 198 |
| Abdominoperineal resection | 45~(26.8%) | 9 (30.0%) | 1.21 [0.54; 2.69] | 0.640 | 0.72 [0.21; 2.49] | 0.603 | |
| Hartmann | 10 (5.95%) | 3 (10.0%) | 1.91 [0.56;6.47] | 0.301 | 1.47 [0.39; 5.54] | 0.568 | |
| Perforation | 3 (1.79%) | 2(6.67%) | 2.59 [0.62;10.9] | 0.193 | 2.83 [0.58;13.76] | 0.196 | 198 |
| Invasion circumferential margin | 10 (5.99%) | 8 (26.7%) | 4.23 [1.88;9.52] | < 0.001 | 2.53 [0.95; 6.73] | 0.062 | 197 |
| Mesorrecto quality: | , , | ` , | | | | | 198 |
| Partial | 42~(25.0%) | 9 (30.0%) | 1.22 [0.56; 2.66] | 0.620 | 0.90 [0.38; 2.11] | 0.8 | |
| No-satisfactory | 3 (1.79%) | 0 (0.00%) | 0.00 [0.00;.] | 0.997 | 0.00 [0.00; Inf] | 0.999 | |

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 2: Metastasis




Table 4: According to Exitus

| | | | Crude | | Multivaria | te | |
|---------------------------------|------------------|----------------|-------------------|---------|-------------------------|---------|-----|
| | No event $n=161$ | Event n= 37 | HR | p-value | HR | p-value | N |
| Age (10y) | 6.60 (1.05) | 6.98 (1.20) | 1.36 [0.99;1.88] | 0.061 | 1.30 [0.91; 1.86] | 0.154 | 198 |
| Sex: Men | 129 (80.1%) | 28 (75.7%) | 0.85 [0.40;1.81] | 0.677 | $1.35 \ [0.56; \ 3.26]$ | 0.501 | 198 |
| Tumor level: | , | , | . , , | | , , | | 198 |
| 0-6cm | 60 (37.3%) | 18 (48.6%) | 1.81 [0.53;6.16] | 0.340 | 1.44 [0.24; 8.62] | 0.688 | |
| 7-12cm | 85 (52.8%) | 16 (43.2%) | 1.16 [0.34;3.99] | 0.811 | 1.28 [0.33; 4.88] | 0.721 | |
| Tumor stage: | | | | | | | 198 |
| 0 | 19 (11.8%) | 0 (0.00%) | 0.00 [0.00;.] | 0.997 | 0.00 [0.00; Inf] | 0.996 | |
| II | 47~(29.2%) | 7~(18.9%) | 1.12 [0.39; 3.19] | 0.831 | 1.25 [0.40; 3.90] | 0.698 | |
| III | 39(24.2%) | 23~(62.2%) | 3.84 [1.65;8.96] | 0.002 | 4.05 [1.58;10.39] | 0.004 | |
| Neoadjuvant treatment | 98 (60.9%) | 26 (70.3%) | 1.64 [0.81;3.32] | 0.171 | 1.35 [0.57; 3.19] | 0.497 | 198 |
| Type of resection: | | | | | | | 198 |
| Abdominoperineal resection | 39(24.2%) | 15 (40.5%) | 2.20 [1.10;4.41] | 0.026 | 1.97 [0.53; 7.33] | 0.311 | |
| Hartmann | 8(4.97%) | 5 (13.5%) | 4.12 [1.50;11.3] | 0.006 | 2.60 [0.73; 9.24] | 0.139 | |
| Perforation | 4 (2.48%) | 1(2.70%) | 0.83 [0.11;6.04] | 0.851 | 0.82 [0.10; 6.98] | 0.856 | 198 |
| Invasion circumferential margin | 10 (6.21%) | 8 (22.2%) | 3.02 [1.38;6.65] | 0.006 | 1.42 [0.54; 3.77] | 0.479 | 197 |
| Mesorrecto quality: | ` , | , , | | | | | 198 |
| Partial | 38 (23.6%) | 13 (35.1%) | 1.41 [0.71; 2.80] | 0.320 | 0.88 [0.41; 1.89] | 0.738 | |
| No-satisfactory | 2(1.24%) | 1(2.70%) | 1.41 [0.19;10.5] | 0.736 | 0.31 [0.03; 2.88] | 0.302 | |

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus




Figure 4: Local Recurrence, according to Type of Resection:






Figure 5: Metastasis, according to Type of Resection:

Metastasis




Figure 6: Survival, according to Type of Resection:




Table 5: Incidence by outcome [95% CI]

| Months | Local Recurrence | Metastasis | Exitus |
|--------|-------------------|----------------------|----------------------|
| 11 | 0 [0; 0] | 7.19 [10.89; 3.35] | 3.78 [6.49; 0.99] |
| 23 | 2.4 [4.69; 0.05] | 15.62 [20.88; 10.01] | 9.45 [13.64; 5.07] |
| 35 | 3.77 [6.69; 0.75] | 17.62 [23.19; 11.66] | 15.72 [21.02; 10.06] |
| 48 | 3.77 [6.69; 0.75] | 17.62 [23.19; 11.66] | 18.01 [23.71; 11.88] |
| 60 | 4.83 [8.35; 1.17] | 17.62 [23.19; 11.66] | 24.81 [31.74; 17.17] |